Eurobio Oncology
Prolaris®: Resources for Performing Laboratories
Welcome to the Prolaris® Performing Laboratories Hub
This page is for laboratories that currently perform Prolaris testing. Here, you’ll find technical resources and guidance for authorized Prolaris labs.
As a valued Prolaris partner laboratory, you play a crucial role in helping clinicians worldwide make confident, evidence-based decisions in prostate cancer treatment.1-8
We're Here to Support You
The Prolaris Kit Support Team is available to provide expert guidance and practical assistance whenever needed. We are here to support laboratories in ensuring smooth implementation and reliable performance of Prolaris.
Our team can assist you with:
- Test procedure guidance – including handling steps and workflow setup
- Troubleshooting and support for testing related issues
- Documentation-related questions (e.g. IFUs, SDS)
Documents and Downloads
To support your daily operations and ensure the highest standards in test performance, we provide all key documents in one place:
Instructions for Use (IFU) & Safety Data Sheets (SDS)
- Available in multiple languages
- Include comprehensive handling instructions, kit protocols, and safety guidance
- Regularly updated to reflect the latest regulatory and technical standards
PBRG Report Generator
Existing laboratory partners can upload measured gene expression data via the Prolaris Biopsy Report Generator (PBRG) to create the RNA quality report, the result report and the summary report.
How to Order Prolaris® Kits
export@eurobio-scientific.com
Austria
adv@eurobio-scientific.com
France
export@eurobio-scientific.com
Germany
oncology@did.it
Italy
info@tecomedical.com
Switzerland
export@eurobio-scientific.com
Global
Pathologists who are already trained and set up to perform the Prolaris test in their own laboratories can order Prolaris kits directly. Please note that kits are available only for laboratories with established implementation and trained personnel!
Performing laboratories can place orders via the email addresses listed below. All order numbers, forms, and procedures were provided during the official implementation process.
References
- Cuzick J, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011
- Lin DW, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol. Oncol. 2018
- Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012
- Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managedneedle biopsy cohort. Br J Cancer. 2015
- Tward JD, et al. Personalizing localized prostate cancer: Validation of a combined clinical cell-cycle risk (CCR) score threshold for prognosticating benefit from multimodality therapy. Clin Genitourin Cancer. 2021
- Tward JD, et al. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int J Radiat Oncol Biol Phys. 2022
- Crawford ED. Et al.: Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer: Results From an Ongoing Registry. Curr Med Res Opin 2014
- Scientific Publications | Myriad Genetics
English (UK)